Kubota Pharmaceutical will sell specially designed glasses dubbed Kubota Glass, which it claims are able to reverse the effects of myopia.
The glasses shine tiny lights at the retina to simulate short-distance blurring, forcing the user to look further ahead and in doing so taking the pressure of the axial deformation of eyeballs.
Long-term testing is still required to gauge how effective Kubota Glass is at this in detail, but studies so far suggest that they are at least effective at curbing the progression of myopia.
Kubota Glass has been approved as a medical device in Taiwan and the USA.
Kubota Pharmaceutical charges 770,000 yen for a pair of Kubota Glass while offering a 100-percent satisfaction guarantee.
According to 2009 research conducted by Japan's Ministry of Education, Culture, Sports, Science, and Technology, around 25% of first-graders had less than perfect eyesight, with the percentage rising to 50% among sixth-graders.


Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback
Neuralink Expands Brain Implant Trials with 12 Global Patients
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
South Korea Warns Weak Won Could Push Inflation Higher in 2025
Japan Inflation Holds Firm in November as BOJ Nears Key Rate Hike Decision
Austan Goolsbee Signals Potential for More Fed Rate Cuts as Inflation Shows Improvement
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
U.S. Stock Futures Edge Higher as Micron Earnings Boost AI Sentiment Ahead of CPI Data
Gold and Silver Surge as Safe Haven Demand Rises on U.S. Economic Uncertainty
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 



